Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)

Summary

The study is conducted to compare safety and efficacy of isoniazid administered as an adjusted dose based on NAT2 (arylamine N-acetyltransferase type 2)genotype and as a standard dose. The hypothesis is that the genotype-adjusted dose is superior to the standard dose with regard to hepatotoxicity and early treatment failure, respectively, in the group of slow and rapid acetylators of NAT2.

Timeline

Start

2008-06

Primary completion

2011-12

Completion

2012-02

Outcome

Outcome not reported

Stopped (Enrollment): “Enrolling participants has halted prematurely due to a low recruitment rate.”

Drugs

Indications